TY - JOUR T1 - <em>Ex Vivo</em> Expansion of Antitumor Cytotoxic Lymphocytes with Tumor-associated Antigen-loaded Dendritic Cells JF - Anticancer Research JO - Anticancer Res SP - 2177 LP - 2185 VL - 25 IS - 3B AU - ALBAN GERVAIS AU - FRANÇOISE BOUET-TOUSSAINT AU - OLIVIER TOUTIRAIS AU - CÉCILE THOMAS DE LA PINTIERE AU - NOELLE GENETET AU - VÉRONIQUE CATROS-QUEMENER Y1 - 2005/05/01 UR - http://ar.iiarjournals.org/content/25/3B/2177.abstract N2 - Cell therapy with lymphocytes is an attractive approach for cancer immunotherapy. Methods to generate ex vivo effector cells directed against whole autologous tumor antigens are under investigation. Our procedure involved stimulation of autologous lymphocytes with antigen-pulsed dendritic cells (DC). Experimental conditions were established with DC, matured with TNFα, LPS and CD40L, from healthy donors and the M74 melanoma cell line. DC were pulsed with either irradiated, apoptotic or necrotic tumor cells or fused with tumor cells. Increase of lymphocyte cytotoxicity and IFNγ production were repeatedly observed with tumor cell-loaded DC. Stimulation of tumor-associated antigen-specific lymphocytes was clearly shown. MelanA-MART1 (dominant melanoma-associated antigen) tetramer staining revealed a high frequency of specific T cells. Lymphocytes were able to efficiently lyse MelanA-MART1-pulsed T2 target and MelanA-expressing target cells (M74) after CD56+ cells depletion. We confirmed with other tumor cell lines that this DC-mediated procedure induced activation of cytolytic lymphocytes. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved ER -